Healthcare industry

The German Cancer Research Centre and the Spanish company Chimera Pharma SL have signed an exclusive licensing and cooperation agreement. The two partners will develop a therapeutic vaccine against cervical cancer.

Article - 14/10/2011

Vetter - a world market leader: “We put ourselves in our clients’ shoes"

We talked with Peter Soelkner Managing Director of Vetter Pharma International GmbH. Soelkner has been with Vetter since 2008. Prior to his current position Soelkner was the head of Key Account Management at Vetter before going on to work for Sartorius Stedim Biotech USA. The sales specialist has a chemical engineering degree and an MBA from Columbia University NY.

Press release - 03/12/2009

ELARA Pharmaceuticals receives EUR 4.6 Million funding

ELARA Pharmaceuticals GmbH, a biotech company focused on the development of drugs for the treatment of different cancers, announced today the closing of a € 2.6 million Series A financing round, which will trigger an additional € 2 million from the BMBF GOBio and the Biotechnologie Rhein-Neckar (BioRN) Spitzencluster programs, leading to a total funding of € 4.6 million.

Press release - 09/07/2008

Rentschler to focus on biotechnology

Rentschler has sold all its Rentschler Pharma GmbH shares to RIEMSER AG in Greifswald. With this move Rentschler is concentrating all its biotech activities at one site and thus providing the framework for further growth. In 2006 Rentschler sold its self-medication business.

Press release - 03/09/2010

Vetter opens new sales office in suburban Chicago

Vetter is combining its U.S. activities in the emerging pharmaceutical and biotechnology region of Illinois: Vetter has opened a new sales office in suburban Chicago to focus on its strategy of U.S. growth and expansion.

Article - 27/10/2014

Takeda GmbH in Singen – pharmaceutical development and production under one roof

From stomach protection agents to drugs for the treatment of respiratory distress in preterm infants – Singen-based Takeda GmbH plays an important role as a competence centre for drugs in liquid and semi-solid dosage form within the Japanese pharmaceutical company’s global network. Besides the production of around 68 million packages per year, the company’s production site in Singen also focuses on drug development. The company’s CMC Centre…

The second Science to Market Conference took place in Hannover, Germany, on October 6 – 7, 2009. The aim of the conference was the promotion of cooperation between academia and industry in the area of pharmaceutical biotechnology.

Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.

The German Cancer Research Centre and Bayer Schering Pharma AG signed an agreement to establish a strategic research alliance. The partners will invest a total of 3.5 million euros in cooperative cancer research over the next two years.

Press release - 04/11/2010

Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

Press release - 16/11/2015

The Baden-Württemberg healthcare industry – a strong economic power

(Stuttgart – 16th November 2015) BIOPRO Baden-Württemberg has just published its latest analysis of the Baden-Württemberg healthcare industry including comprehensive facts and figures. Baden-Württemberg continues to be one of the top locations for medical technology, pharma and biotechnology in Germany.

About a year ago Prof. Dr. Martin Schwemmle and his team at the University Hospital of Freiburg discovered a new starting point in the fight against the H5N1-virus. In the meantime the scientists are working together with the company Pike Pharma to develop a compound.

The 14th annual edition of BIO-Europe which toke place in Mannheim strengthened its claim to being the worlds largest stand-alone partnering event with the participation of 1250 biotech pharma and professional service organizationsa and 190 company presentations.

The Ravensburg-based company Vetter Pharma-Fertigung GmbH & Co. KG is one of the leaders in biopharmaceutical contract manufacturing. We spoke with Max Horn, who has been with the company since 1981 and was appointed Managing Director in 2002.

Press release - 12/11/2009

SYGNIS reports on second quarter 2009/2010

Heidelberg, November 10, 2009 – SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today published its financial results for the second quarter and the first half of the fiscal year 2009/2010, which ended on 30 September 2009.

Press release - 05/12/2011

Flexible Rack Systems Sort Molecules

Researchers of Karlsruhe Institute of Technology (KIT) and Ruhr-Universität Bochum (RUB) have developed a flexible and efficient new process for the separation of enantiomers. Enantiomer separation is indispensable for the production of many pharmaceuticals. In their process, the scientists use porous molecular frameworks (MOFs) that are assembled in layers on solid substrates using a specifically developed method. The results have now been…

Nycomed signs an agreement for the acquisition of Laboratorios Farmacol S.A. located in Colombia to further grow its presence in the Latin American region. Farmacol S.A., a Colombia based pharmaceutical company, has a strong presence in the areas of gastroenterology, respiratory and gynaecology.

Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.

Innovative Therapies - 20/08/2020

Labor Dr. Merk is fully committed to viral therapies

Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

Vetter Pharma Fertigung a Ravensburg-based specialist in the production of aseptically pre-filled injection systems is strengthening its commitment to the North American market. Laupheim-based Rentschler Biotechnologie a contract research organisation that has been continuously expanding since 2006 has further investment plans.

Press release - 30/01/2017

ChemCon celebrates 20th anniversary

ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…

Press release - 01/08/2012

Combination of businesses of SYGNIS and GENETRIX’ subsidiary X-Pol proposed

SYGNIS Pharma AG and GENETRIX announced today, that the biotechnology companies SYGNIS and GENETRIX have signed a binding Term Sheet under which the companies propose to combine the GENETRIX’ DNA sequencing subsidiary X-Pol Biotech and SYGNIS. Goal is to develop and market X-Pol Biotech, S.L.’s DNA sequencing technologies and products.

High-tech - 20/10/2016

Industry 4.0 in the medical technology and pharmaceutical industry sectors

The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.

Press release - 31/05/2010

New antibody for the treatment of multiple myeloma

Boehringer Ingelheim and Micromet have entered into a collaboration for the research development and commercialisation of a new antibody-based treatment of multiple myeloma a cancer of the bone marrow that remains largely incurable.